Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138093 | 0.93 | TSHR (0.43) | HSD11B1SMPD1TSHRL3MBTL1 | |
| SCHEMBL5135920 | 0.92 | BCHE (0.44) | BCHEHSD11B1TSHR | |
| SCHEMBL5075074 | 0.92 | TSHR (0.46) | BCHEHSD11B1TSHR | |
| SCHEMBL5072355 | 0.91 | HSD11B1 (0.45) | BCHEHSD11B1TSHRL3MBTL1 | |
| SCHEMBL5135239 | 0.91 | BCHE (0.47) | BCHESIGMAR1 | |
| SCHEMBL5135667 | 0.90 | HSD11B1 (0.44) | BCHEHSD11B1TSHRL3MBTL1 | |
| SCHEMBL5134920 | 0.90 | HSD11B1 (0.44) | BCHEHSD11B1TSHRKCNH2 | |
| SCHEMBL5073933 | 0.88 | HSD11B1 (0.43) | BCHEHSD11B1TSHRL3MBTL1 | |
| SCHEMBL5137544 | 0.87 | HSP90AA1 (0.39) | BCHETSHRL3MBTL1 | |
| SCHEMBL5072318 | 0.87 | TSHR (0.40) | HSD11B1SMPD1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |